- Home
- GIGM vs CTXR Comparison
GIGM vs CTXR Comparison
Compare GIGM & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | CTXR |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 16.8M |
| IPO Year | 2002 | 2010 |
Fundamental Metrics
Financial Performance| Metric | GIGM | CTXR |
|---|---|---|
| Price | $1.52 | $0.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 5.4K | ★ 578.8K |
| Earning Date | 01-01-0001 | 06-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.38 | $0.63 |
| 52 Week High | $1.89 | $2.38 |
Technical Indicators
Market Signals| Indicator | GIGM | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 40.91 | 49.42 |
| Support Level | $1.49 | $0.70 |
| Resistance Level | $1.58 | $0.98 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 61.11 | 42.64 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.